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Alzheimer's - The Cholinergic Hypothesis and Gene — Targeting Stem
Cell Treatment
Richa Gautam and Emma Nichols
Vassar College
As the mean age of the world population rises and people's life expectancies increase, the prevalence ofAlzheimer's
disease will increase and will pose a threat to society in terms of the people affected and the money used. Current
therapies are not adequate in that they are unable to extend life beyond a few months. This review will both
overview the predominant hypotheses about how to approach the treatment ofAlzheimer's as well as discuss some of
the treatments available and those in preclinical phases. Finally, we will discuss the ideas and recent research behind
gene therapy and stem cell therapy as well as the new ways in which these two methods have been combined and
could be combined in the future to create a more effective approach to treating Alzheimer's.
Alzheimer's disease is the most common
neurodegenerative disorder worldwide (JakobRoetne & Jacobsen, 2009). As it is most
frequent in old age, the changing population
demographics lead to concerns regarding the
occurrence rate and lack of a cure.
Alzheimer's is a type of dementia and normally
presents symptoms of memory loss and ability
to learn and reason. This can cause patients to
lose understanding of who they are, who others
are and where they are, causing panic and
distress (Chen & Blurton-Jones, 2012). This
creates many problems for Alzheimer's
patients and their loved ones and these issues
have prompted much research in the field of
Alzheimer's disease over the past few decades.
Amyloid Hypothesis
Much of the research regarding Alzheimer's
has focused on the workings and implications
of the amyloid hypothesis. The hypothesis
posits that the accumulation of the amyloidbeta peptide (A13) in the central nervous system
(CNS) triggers a cascade of events that leads to
cell death. The series of events that leads to the
excess Ai3 begins with the 13-amyloid precursor
protein, which occurs in different variants, all
of which can be spliced into different versions
of A13 (Jakob-Roetne et al., 2009). Although
A13 is not toxic at the standard physiological

concentration,
with
the
increased
concentration present in Alzheimer's, it causes
neuronal degeneration. However, all processes
that cause increased APP levels and therefore
A13 levels are not currently known, though
mutations in the APP gene play a factor in
genetic cases of AD (Borlongan, 2012).
A(342 is a longer variant of the Ap peptide,
which is most susceptible to aggregation,
which is the process that eventually leads to cell
death. Instead of forming an a-helix as the
peptides usually do, they form [3-sheets, which
come together to form toxic amyloid plaques
(Jakob-Roetne et al., 2009). The accumulation
of these plaques then set off a chain of events
that lead to neuronal dysfunction, inability to
perform long- term potentiation (a function
that is critical for memory) and finally
neurodegeneration (Jakob-Roetne et al., 2009,
p. 3041).
Although the buildup of toxic amyloid
plaques clearly plays an important role in the
pathology of Alzheimer's, there are also clearly
other important co-pathologies. The best
researched among them is the buildup of
neurofibrillary tangles caused by the overphosphorylation of the tau protein (JakobRoetne et al., 2009). However, this is only one
of the many other observed pathological
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differences in AD and it is not yet known
which change is the root cause. Because of lack
of definitive information regarding the initial
trigger and cause of Alzheimer's, many current
treatments function as palliative treatments
and attempt to work to stop the process of
neurodegeneration not by addressing the
underlying pathology but instead looking to
aid and replenish the areas of the brain most
devastated by neuronal death. Although
palliative treatments will never constitute a
permanent cure for Alzheimer's, because of the
current lack of a permanent cure, they provide
an important means by which to delay the
progression of the disease. Even upon the
eventual discovery of the treatment for the
underlying pathology of Alzheimer's, it will be
critical to have palliative treatments available to
slow the progress of the disease in order to give
time for the cure to function.
Cholinergic Hypothesis
The most popular palliative treatments for
Alzheimer's are directed towards the
cholinergic hypothesis, which posits that a
significant loss of cholinergic neurons in the
CNS is a primary contributor to the cognitive
symptoms of Alzheimer's (Bartus, 2000). The
treatments directed at this hypothesis, which
include cholinesterase inhibitors, are one of the
few current treatments for Alzheimer's that
have been approved by the FDA.
There exists much evidence that points to the
idea that the loss of cholinergic neurons in the
CNS and particularly in the basal forebrain
contributes to a loss of cognitive function.
Since the mid-1990s, studies have shown that
the severity of degradation of cholinergic
neurons correlates to the clinical severity of
Alzheimer's before death, the deposition of
neurofibrillary tangles and well as amyloid
plaques (Frolich, 2002). This suggests that the
amyloid hypothesis and the cholinergic
hypothesis are connected and that both are

somehow related to the pathophysiology of the
disease.
Furthermore, recent longitudinal studies have
indicated an initial plasticity and subsequent
loss of plasticity in the cholinergic system. The
study looked at the levels of choline
acetyltransferase (ChAT), which is an enzyme
that facilitates the creation of acetylcholine
from acetyl-CoA and choline. The results
showed an increase in ChAT levels in cases of
mild cognitive impairment and mild AD, but
normal levels in cases of moderate to severe
AD. Scientists concluded from this data that
the brain initially attempts to compensate for
lower acetylcholine (ACh) levels by
upregulating ChAT, but that as the disease
progresses the brain is unable to sustain the
process of compensation (Frolich, 2002).
Therefore, palliative treatments that continue
to compensate for ACh reduction would be
effective in suppressing the cognitive
symptoms of AD.
Treatments
Drug treatments
After the identification of Alzheimer's as a
disease, the search for a cause and subsequently
a treatment began. However, since research
into causes has not led to one distinct answer
but instead multiple observations about the
neural systems effected during AD, drug
treatments of three distinct types were
developed — drugs that acted as indirect ACh
agonists and inhibited the action of ACh
esterases, drugs that block the formation of
amyloid plaques, and drugs that inhibit
NMDA receptors (Taupin, 2009). But while
all the three types of drugs are effective to some
extent in alleviating the symptoms of
Alzheimer's, they are unable to stop the
progress of the disease.
Gene therapy
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Alzheimer's has been observed to be
heritable to an extent, and that has spurred
research on possible genetic markers. While
different genes have been associated with
Alzheimer's, there has not been enough
research to identify definite genetic causes.
Therefore, current gene therapy research
instead focuses on the causes proposed by the
different hypotheses. One type of gene therapy
that has been developed recently involves
genetically modifying cells to produce more
acetylcholine. Fu et al. (2004) transplanted a
ChAT overexpression gene in bacteria and
injected the vector bacteria into mice treated
with A13 to induce Alzheimer-like cognitive
deficiencies. The researchers observed that the
vector bacteria successfully crossed the bloodbrain barrier and post mortem neural analysis
shows successful expression of the gene in
some neurons in the brain. The mice treated
with the bacteria vector also showed improved
cognitive abilities. In addition to testing gene
therapy, this study also showed that increasing
ChAT levels in specific areas of the brain could
help alleviate cognitive deficiencies induced by
Alzheimer's.
Other proteins currently being targeted in
gene therapy are nerve growth factor (NGF)
and brain-derived neurotrophic factor
(BDNF). Both of these molecules have been
associated with synaptic plasticity (Chen et al.,
2012), and NGF has been shown to decrease
neuronal cell death (Kim, Lee & Kim, 2013).
Stem-cell treatment. Stem cells are one of the
most recent treatment options for
neurodegenerative diseases. The cell death in
AD is not limited to a specific type of neurons.
Since stem cells can divide and differentiate
into a variety of cell types, they seem a
reasonable solution this widespread neuronal
cell death. Different groups of researchers have
independently found that transplantation of
multipotent stem cells (MSCs) transplanted
into the brains of rat models of AD led to both

reduction of A13 deposition and tau
hyperphosphorylization. Furthermore, this
treatment also led to improvements in memory
and spatial learning among the rats (Glat &
Offen, 2013).
Additionally, stem cells can be genetically
modified in order to also counter some of the
chemical effects of Alzheimer's, like the
decrease in cholinergic sensitivity.
Genetic modifications can also increase the
levels of specific neurotrophic factors by
increasing production of those molecules. By
combining stem cell treatment and gene
therapy through genetic modification of stem
cells, it is possible to take advantage of both the
benefits of using stem cells to replace areas of
prevalent neuronal death as well as the benefits
of increasing the production of specific
proteins known to help treat the cognitive
symptoms of AD.
Recent research has found that
transplanting stem cells producing more
ChAT helped improve working memory in
mice with lesions imitating neuronal cell death
in Alzheimer's (Wang et al., 2006; as cited in
Kim et al., 2013), transplanting cells with
increased production of NGF improved
memory in rats (Wu et al., 2006; as cited in
Kim et al., 2013), and transplanting cells
producing more BDNF improved working
memory in mice (Blurton-Jones et al., 2006; as
cited in Kim et al., 2013). In 2012, Park et al.
conducted an experiment with rats that were
injected with kainic acid to induce neuronal
cell death akin to that in Alzheimer's. Four
weeks later, neural stem cells (NSCs)
genetically modified to produce excess of
ChAT were transplanted in the lesioned areas.
The rats were tested for learning and memory.
Over a few weeks, the rats showed full
restoration of ACh levels in the brain and their
learning and memory capacities improved to a
level comparable to normal rats (Glat et al.,
2013, p. 1492). A similar study conducted that
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same year found that transplanting NSCs
producing more NGF in mice had similar
effects as those seen when ChAT
overexpressing NSCs were implanted (Lee et
al., 2012; as cited in Kim et al., 2013).
However, stem cell treatment faces its own
obstacles. Stem cells have been the center of
ethical debates for a while now. While the
human brain does have some amounts of
naturally occurring NSCs, suggesting that
inducing neurogenesis in AD patients could be
a possible cure (Glat et al., 2013), the
possibility of AD having genetic markers
diminishes the capacity for these NSC to
successfully fill in for areas of neuronal death.
It is possible to take the naturally occurring
NSCs and genetically modify them, but the
amount of such NSCs available is still low
compared to the levels of cell death.
Umbilical cords have some amounts of
MSCs, but not a lot of research has used
umbilical cord MSCs. Stem cells can be
harvested from embryos but there has been
much pushback on this subject because of
issues of ethics.
A further problem regarding stem cell
transplant is that it is unpredictable. Since stem
cells can differentiate into a variety of different
types of cells, there is no way to fully regulate
the differentiation process to only form the
specific subtype or subtypes needed. Recent
research has focused a lot on generating
specific subtypes of neurons from stem cells.
Bissonnette et al. (2011) generated functional
basal forebrain cholinergic neurons from
embryonic stem cells with a success rate of
85%. They also stated that with additional
controls, the success rate could be increased to
94%. However, this differentiation was carried
out in a culture medium and not after
transplantation. In 2013, Crompton et al.
carried out successful controlled differentiation
of transplanted NSCs using sonic hedgehog
(SHH) signaling, the basic premise being that
in an embryo the stem cells differentiate into

specific neuronal subtypes due to SHH
signaling. This research suggests that it may be
possible to take advantage of the chemicals
involved in SHH signaling to control the
differentiation of stem cells.
Once transplanted, it is difficult to ensure
that the cells travel to the appropriate places
and form the appropriate neural connections.
Without the appropriate neural connections,
the overexpression of chemical factors will not
be as effective. Though Park et al. (2012)
found a more than 96% success rate in the
appropriate migration and differentiation of
transplanted NSCs, this research was done on
an animal model and such high success rates
need to be replicated by multiple studies before
the treatment can be tried on humans. Some of
the pathologies associated with AD might be
affecting the success of proliferation and
differentiation of transplanted cells. Few
studies have investigated the effect of A13 on
transplanted cells and while some showed that
it hindered proliferation and transplantation
(Haughey et al, 2002; as cited in Glat et al.,
2013), another study showed that it helps in
successful proliferation and degradation Gin et
al., 2004; as cited in Glat et al., 2013),
suggesting that AP oligomers help in
proliferation and differentiation, but as the
disease progresses, the fibrils formed from Ap
lead to cell death.
It is additionally possible that if embryonic
stem cells from a stem cell bank are used, the
transplanted cells will also be unrecognizable
to the immune system and therefore may lead
to an immunological response. Because of this
complication, researchers have been focused on
learning to use stem cells found naturally in the
muscles, or on taking skin cells and inducing
them to pluripotency, creating induced
pluripotent stem cells (iPSC). Since these stem
cells have the same genetic makeup as the rest
of the body's cells, the body recognizes them as
its own and therefore no immunological
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response is elicited. However, the other
problems of specific differentiation and
formation of appropriate connections remain.

Discussion
The lack of clarity in terms of the causes of
Alzheimer's has hindered the search for a cure
till now. Palliative drug treatments have helped
in alleviating the symptoms of the disease, but
there is still no cure for AD. While gene
therapy has had some success on animal
models, more research is needed on the specific
functionality of these different proteins and
how they affect the pathophysiology of AD.
Furthermore, studies should be done to
address the potential benefits of combining
different gene therapies and using them
together to create a multi-pronged approach to
treating AD. More research also needs to be
done on the combination of gene therapy and
stem cell treatment in Alzheimer's. Of
particular interest is how different genetic
changes can be incorporated together to affect
the same group of stem cells in order to create
a multi-pronged approach to the treatment of
Alzheimer's. The idea would be that hopefully
by combining these smaller scale successes, a
more long-lasting and overarching treatment
could be found which could potentially arrest
the progress of the disease. Despite the
problems associated with the use of stem cells
in neurodegenerative diseases, these
approaches to treating Alzheimer's are
incredibly promising. The use of stem cells is
currently the only known method of reversing
the effects of neuronal death, and when those
effects are combined with the effects of gene
therapy using genetically modified cells, there
is a great potential for a the creation of a
treatment more effective than anything that is
currently available. The goal of this new
treatment would be to create a long-term
palliative treatment that could arrest the rapid

advance of Alzheimer's, and possibly add years
onto the lives of patients. There is still much
investigation that needs to be done, including
moving the research from animal models to
human trials and further experimenting with
the combination of the different genetic
alterations. However, the research already
completed provides a solid foundation that
shows great potential for the development of a
new, cutting-edge treatment for Alzheimer's.
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